{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:34:52Z","timestamp":1788352492009,"version":"build-2803163510"},"reference-count":285,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in predominantly epigenetic regulator, RNA splicing and signaling pathway genes. These molecular mutations are a hallmark of diagnostic, prognostic, and therapeutic assessment in patients with MPNs. Over the past decade, next generation sequencing (NGS) has identified multiple somatic mutations in MPNs and has contributed substantially to our understanding of the disease pathogenesis highlighting the role of clonal evolution in disease progression. In addition, disease prognostication has expanded from encompassing only clinical decision making to include genomics in prognostic scoring systems. Taking into account the decreasing costs and increasing speed and availability of high throughput technologies, the integration of NGS into a diagnostic, prognostic and therapeutic pipeline is within reach. In this review, these aspects will be discussed highlighting their role regarding disease outcome and treatment modalities in patients with MPNs.<\/jats:p>","DOI":"10.3390\/cancers12082194","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T09:41:21Z","timestamp":1596706881000},"page":"2194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"Vibe","family":"Skov","sequence":"first","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, Vestermarksvej 7-9, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_4","first-page":"1","article-title":"Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediators Inflamm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ejh.12437","article-title":"Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"94","author":"Hasselbalch","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"\u00d8bro, N.F., Grinfeld, J., Belmonte, M., Irvine, M., Shepherd, M., Rao, T.N., Karow, A., Riedel, L.M., Harris, O., and Baxter, E.J. (2020). Longitudinal Cytokine Profiling Identifies GRO-\u03b1 and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. HemaSphere, 4.","DOI":"10.1097\/HS9.0000000000000371"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-008-0498-4","article-title":"Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera","volume":"87","author":"Larsen","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Expert Rev. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha\u20132a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2040620719870052","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Knudsen, T.A., Hansen, D.L., Ocias, L.F., Bjerrum, O.W., Brabrand, M., El Fassi, D., Frederiksen, M., Kj\u00e6r, L., Kristensen, T.K., and Kruse, T.A. (2018). Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyures in polycythemia vera: Preliminary results from the three-year analysis of the DALIAH trial - a randomized controlled phase III clinical trial. Blood, 132.","DOI":"10.1182\/blood-2018-99-111255"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_36","first-page":"1","article-title":"Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?","volume":"8","author":"Hasselbalch","year":"2015","journal-title":"Expert Rev. Hem"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/cam4.2741","article-title":"Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms","volume":"9","author":"Pedersen","year":"2020","journal-title":"Cancer Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2012.064683","article-title":"Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood.2019002561","article-title":"Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning","volume":"135","author":"Bridgford","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.clml.2017.02.015","article-title":"Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms","volume":"17","author":"Patel","year":"2017","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4274\/balkanmedj.galenos.2018.2018.1195","article-title":"The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies","volume":"36","author":"Alkan","year":"2019","journal-title":"Balkan Med. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11899-015-0256-3","article-title":"Next-generation sequencing-based panel testing for myeloid neoplasms","volume":"10","author":"Kuo","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., and Birnbaum, D. (2012). Myeloid malignancies: Mutations, models and management. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-304"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.5858\/arpa.2014-0096-RA","article-title":"Molecular genetic biomarkers in myeloid malignancies","volume":"139","author":"Matynia","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_57","unstructured":"Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., Sant\u2019Antonio, E., Guglielmelli, P., and Vannucchi, A.M. (2020). RAS\/MAPK Pathway Mutations are Associated with Adverse Survival Outcomes and may Predict Resistance to JAK Inhibitors in Myelofibrosis. EHA Abstr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10428194.2018.1522437","article-title":"Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis","volume":"60","author":"Wanquet","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/gcc.22789","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","volume":"59","author":"Courtier","year":"2020","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.16450","article-title":"ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients","volume":"189","author":"Andreasson","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience","volume":"4","author":"Alduaij","year":"2018","journal-title":"HemaSphere"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00277-017-2937-6","article-title":"Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: Data from targeted next-generation sequencing in the diagnostic laboratory","volume":"96","author":"Agarwal","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.11.022","article-title":"Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms","volume":"86","author":"Boiocchi","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11899-011-0108-8","article-title":"Role of TET2 mutations in myeloproliferative neoplasms","volume":"7","author":"Pronier","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The Molecular Genetics of Myeloproliferative Neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"Langabeer","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1038\/bcj.2016.75","article-title":"Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing","volume":"6","author":"Angona","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","article-title":"Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels","volume":"44","author":"Inoue","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"30941","DOI":"10.1074\/jbc.M112.366625","article-title":"Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation","volume":"287","author":"Matje","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.16276","article-title":"Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression","volume":"188","author":"Cottin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2013.80","article-title":"Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","article-title":"Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo","volume":"27","author":"Shirai","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41375-018-0283-x","article-title":"Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis","volume":"33","author":"Szuber","year":"2019","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41375-019-0668-5","article-title":"Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis","volume":"34","author":"Bartels","year":"2020","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis","volume":"147","author":"Song","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/gcc.22437","article-title":"Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome","volume":"56","author":"Chauveau","year":"2017","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.21873\/anticanres.13837","article-title":"The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms","volume":"39","author":"Byun","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00277-018-3563-7","article-title":"Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis","volume":"98","author":"Gill","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2017.298","article-title":"Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2","volume":"32","author":"Bartels","year":"2018","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbmt.2020.03.007","article-title":"Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplant","volume":"26","author":"Stevens","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.3324\/haematol.2018.202952","article-title":"Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease","volume":"104","author":"Stengel","year":"2019","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2013.281","article-title":"Functional and cancer genomics of ASXL family members","volume":"109","author":"Katoh","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Brecqueville","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: Chronology of clonal emergence and changes in mutant allele burden over time","volume":"135","author":"Lasho","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3109\/10428194.2015.1091932","article-title":"Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden","volume":"57","author":"Nussenzveig","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ajh.22058","article-title":"Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jmoldx.2016.08.006","article-title":"Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia","volume":"19","author":"Usseglio","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1080\/10428194.2019.1633634","article-title":"Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy","volume":"60","author":"Novotny","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.15954","article-title":"Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots","volume":"186","author":"Beucher","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/j.seminhematol.2016.10.002","article-title":"Clonal hematopoiesis","volume":"54","author":"Jan","year":"2017","journal-title":"Semin. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Craver, B.M., El Alaoui, K., Scherber, R.M., and Fleischman, A.G. (2018). The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers (Basel)., 10.","DOI":"10.3390\/cancers10040104"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Ferrone, C.K., Blydt-Hansen, M., and Rauh, M.J. (2020). Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020626"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2017.11.002","article-title":"An inflammatory environment containing TNFalpha favors Tet2-mutant clonal hematopoiesis","volume":"59","author":"Abegunde","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of Myeloproliferative Neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2012.02.028","article-title":"Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm","volume":"148","author":"Hou","year":"2012","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2014.289","article-title":"Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia","volume":"29","author":"Engle","year":"2015","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - Impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.clml.2016.02.031","article-title":"Prognosis of Primary Myelofibrosis in the Genomic Era","volume":"16 Suppl.","author":"Bose","year":"2016","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of Mutation Order on Myeloproliferative Neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3324\/haematol.2013.092379","article-title":"Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes","volume":"98","author":"Merker","year":"2013","journal-title":"Haematologica"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/leu.2014.7","article-title":"Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ejh.12425","article-title":"Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera","volume":"94","author":"Angona","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Kirschner, M.M.J., Schemionek, M., Schubert, C., Chatain, N., Sontag, S., Isfort, S., Ortiz-Bruchle, N., Schmitt, K., Kruger, L., and Zerres, K. (2015). Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123476"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","article-title":"Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome","volume":"101","author":"Asp","year":"2016","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2015.207","article-title":"Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN","volume":"30","author":"Jeromin","year":"2016","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmoldx.2016.05.006","article-title":"Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation","volume":"18","author":"Magor","year":"2016","journal-title":"J. Mol. Diagnostics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Nivarthi","year":"2016","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/s41598-017-02655-7","article-title":"A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm","volume":"7","author":"Casolari","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-017-0944-z","article-title":"Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms","volume":"34","author":"Chang","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation","volume":"23","author":"Panagiota","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: A post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet. Haematol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jare.2017.04.001","article-title":"Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review","volume":"8","author":"Zaidi","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fonc.2018.00032","article-title":"Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature","volume":"8","author":"Bonamino","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: A French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjh.14723","article-title":"Mutation profiling by targeted sequencing of \u201ctriple-negative\u201d essential thrombocythaemia patients - supplemental","volume":"181","author":"Ju","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: Association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-018-0152-x","article-title":"Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea","volume":"8","author":"Pacilli","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Bellosillo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: A 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.25580","article-title":"Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms","volume":"94","author":"Acha","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"ref_169","first-page":"4202","article-title":"Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response","volume":"134","author":"Knudsen","year":"2019","journal-title":"Blood (ASH Annu. Meet. Abstr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.3324\/haematol.2018.197699","article-title":"Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: A single center prospective cohort experience","volume":"104","author":"Mansier","year":"2019","journal-title":"Haematologica"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.13318","article-title":"Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation","volume":"103","author":"Mannina","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood.2019001861","article-title":"The poor outcome in high molecular risk, hydroxycarbamide-resistant\/intolerant ET is not ameliorated by ruxolitinib","volume":"134","author":"Hamblin","year":"2019","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing","volume":"73","author":"Buck","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Cassinat, B., Verger, E., Maslah, N., Gauthier, N., Vainchenker, W., Giraudier, S., and Kiladjian, J.-J. (2020). CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica.","DOI":"10.3324\/haematol.2020.252643"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/16078454.2020.1780755","article-title":"Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: Clinicohematologic responses, quality-of-life changes and safety in the real-world setting","volume":"25","author":"Gill","year":"2020","journal-title":"Hematology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_182","unstructured":"Kralovics, R., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., and Pylypenko, H. (2020). Ropeginterferon Alpha-2b is Efficacious and Reduces Variant TET2 Allele Burden in Patients with Polycythaemia Vera and TET2 Mutation: Genetic Analysis of Phase III PROUD-PV\/CONTINUATION-PV Studies. EHA Abstr."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Nonino, A., Campregher, P.V., de Souza Santos, F.P., Mazzeu, J.F., and Pereira, R.W. (2020). Genomic characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis. Int. J. Hematol.","DOI":"10.1007\/s12185-020-02906-w"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Segura-Diaz, A., Stuckey, R., Florido, Y., Gonzalez-Martin, J.M., Lopez-Rodriguez, J.F., Sanchez-Sosa, S., Gonzalez-Perez, E., Saez Perdomo, M.N., Perera, M.D.M., and de la Iglesia, S. (2020). Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A\/TET2\/ASXL1 Mutations. Cancers (Basel), 12.","DOI":"10.3390\/cancers12040934"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.15010","article-title":"Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2017.318","article-title":"Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_194","first-page":"157","article-title":"Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms","volume":"6","author":"Yilmaz","year":"2015","journal-title":"J. Blood Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: Phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Manshouri","year":"2010","journal-title":"Cancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a -2a","volume":"122","author":"Manshouri","year":"2013","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11725","article-title":"Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer","volume":"493","author":"Ruark","year":"2013","journal-title":"Nature"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/ng.2995","article-title":"Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-013-1328-7","article-title":"TET family proteins: New players in gliomas","volume":"116","author":"Bian","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.32507","article-title":"Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients","volume":"146","author":"Sclafani","year":"2020","journal-title":"Int. J. cancer"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/s41467-019-13392-y","article-title":"Functional significance of U2AF1 S34F mutations in lung adenocarcinomas","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e22925","DOI":"10.4161\/jkst.22925","article-title":"The role of JAK-STAT signaling within the CNS","volume":"2","author":"Nicolas","year":"2013","journal-title":"JAK-STAT"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(15)00092-7","article-title":"Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: A population-based cohort study","volume":"2","author":"Frederiksen","year":"2015","journal-title":"Lancet. Haematol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis","volume":"94","author":"Pettersson","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","article-title":"Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients","volume":"29","author":"Yuan","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am. J. Hematol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: A user \u2019 s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_218","first-page":"2489","article-title":"Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms \u2212 Single-center Experience","volume":"34","author":"Kissova","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_219","first-page":"919","article-title":"[Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]","volume":"128","author":"Esteve","year":"2001","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00277-008-0650-1","article-title":"Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients","volume":"88","author":"Spanoudakis","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/102453309X385188","article-title":"Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","article-title":"Hydroxyurea does not appreciably reduce JAK2 v617F allele burden in patients with polycythemia vera or essential thrombocythemia","volume":"95","author":"Antonioli","year":"2010","journal-title":"Haematologica"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","article-title":"Comparative long-term effects of interferon alpha and hydroxyurea on human hematopoietic progenitor cells","volume":"43","author":"King","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European leukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Pereira","year":"2012","journal-title":"Blood"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000226078","article-title":"Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia","volume":"42","author":"Velu","year":"1985","journal-title":"Oncology"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00199157","article-title":"Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders","volume":"25","author":"Ludwig","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(88)91144-0","article-title":"Interferon in myelofibrosis","volume":"1","author":"Hasselbalch","year":"1988","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.1998.tb01039.x","article-title":"Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera","volume":"60","author":"Foa","year":"1998","journal-title":"Eur. J. Haematol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Iversen","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.clml.2019.03.027","article-title":"Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms","volume":"19","author":"Mondello","year":"2019","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: A report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Larsen","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"key":"ref_240","first-page":"2170","article-title":"Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-\u03b1","volume":"118","author":"Riley","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-016-0057-y","article-title":"Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden","volume":"5","author":"Kelley","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp. Hematol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon \u03b1-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/leu.2013.303","article-title":"Use of the 46\/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: Clonal evolution and impact of IFNalpha treatment","volume":"28","author":"Hasan","year":"2014","journal-title":"Leukemia"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.23928","article-title":"Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b","volume":"90","author":"Them","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nm0609-612","article-title":"IFN-alpha wakes up sleeping hematopoietic stem cells","volume":"15","author":"Ernst","year":"2009","journal-title":"Nat. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2011.35.6238","article-title":"Interferon alfa in the treatment of philadelphia-negative chronic myeloproliferative neoplasms","volume":"29","author":"Hasselbalch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri2726","article-title":"Awakening dormant haematopoietic stem cells","volume":"10","author":"Trumpp","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Griesshammer","year":"2016","journal-title":"Haematologica"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: Long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/HS9.0000000000000056","article-title":"Ruxolitinib for the Treatment of Essential Thrombocythemia","volume":"2","author":"Gunawan","year":"2018","journal-title":"HemaSphere"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/oncoscience.373","article-title":"Ruxolitinib for essential thrombocythemia?","volume":"4","author":"Bose","year":"2017","journal-title":"Oncoscience"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3324\/haematol.2015.124099","article-title":"JAK inhibitors and myelofibrosis, Einstein and ruxolitinib","volume":"100","author":"Harrison","year":"2015","journal-title":"Haematologica"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Polverelli, N., Palumbo, G.A., Binotto, G., Abruzzese, E., Benevolo, G., Bergamaschi, M., Tieghi, A., Bonifacio, M., Breccia, M., and Catani, L. (2018). Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematol. Oncol.","DOI":"10.1002\/hon.2509"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/leu.2010.269","article-title":"JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12103","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","volume":"160","author":"Griner","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"500","DOI":"10.18632\/oncotarget.986","article-title":"Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha","volume":"4","author":"Lane","year":"2013","journal-title":"Oncotarget"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Sorensen, A.L., Mikkelsen, S.U., Knudsen, T.A., Bjorn, M.E., Andersen, C.L., Bjerrum, O.W., Brochmann, N., Patel, D.A., Gjerdrum, L.M.R., and El Fassi, D. (2019). Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study. Haematologica.","DOI":"10.3324\/haematol.2019.235648"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"10","author":"Bjorn","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V118.21.2816.2816","article-title":"A mechanistic rationale for the use of statins to enhance JAK inhibitor therapy in MPNs","volume":"118","author":"Griner","year":"2011","journal-title":"Blood"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: General principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_283","first-page":"2972","article-title":"Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs","volume":"134","author":"Skov","year":"2019","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"ref_284","first-page":"73","article-title":"Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera","volume":"3","author":"Ellemann","year":"2014","journal-title":"Leuk. Res. reports"},{"key":"ref_285","first-page":"3643","article-title":"The genetic origin of drug resistance in neoplasms: Implications for systemic therapy","volume":"44","author":"Goldie","year":"1984","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:57:04Z","timestamp":1760176624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":285,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082194"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082194","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]}}}